Brii Bio reports end-of-treatment results for ENRICH and ENHANCE studies

​

Brii Bio has reported topline EOT data from its ongoing Phase IIb ENRICH and ENHANCE trials assessing sequential and concurrent use of BRII-179, elebsiran, and PEG-IFNα to treat chronic HBV infection.

The post Brii Bio reports end-of-treatment results for ENRICH and ENHANCE studies appeared first on Hospital Management.

 

Back to the Featured Stories
Brii Bio reports end-of-treatment results for ENRICH and ENHANCE studies

Featured Stories

Alteogen signs $365m Hybrozyme licensing deal with pharma company
SystImmune doses first patient in Phase III trial for ES-SCLC
SOPHiA GENETICS partners with AstraZeneca for oncology diagnostics
Evexta Bio and Roche plan Phase Ib trial of rupitasertib with giredestrant
Phylo and Chugai collaborate to deploy AI platform in drug discovery

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us